Invention Grant
- Patent Title: Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics
-
Application No.: US16110207Application Date: 2018-08-23
-
Publication No.: US10738325B2Publication Date: 2020-08-11
- Inventor: Clodagh O'Shea , William Partlo , Colin Powers
- Applicant: Salk Institute for Biological Studies
- Applicant Address: US CA La Jolla
- Assignee: Salk Institute for Biological Studies
- Current Assignee: Salk Institute for Biological Studies
- Current Assignee Address: US CA La Jolla
- Agency: Klarquist Sparkman, LLP
- Main IPC: C12N15/86
- IPC: C12N15/86 ; C12N7/00 ; A61K48/00 ; A61K39/00 ; C12N15/62 ; C12N15/63
Abstract:
Recombinant adenovirus genomes that include an exogenous open reading frame (ORF) and a self-cleaving peptide coding sequence are described. Optimal placement of the exogenous genes for minimal impact on viral kinetics is further disclosed. Therapeutic applications of the recombinant adenoviruses are also described.
Public/Granted literature
- US20180355379A1 EXOGENOUS GENE EXPRESSION IN THERAPEUTIC ADENOVIRUS FOR MINIMAL IMPACT ON VIRAL KINETICS Public/Granted day:2018-12-13
Information query
IPC分类:
